 Home > Medical News > Medicines Company News > BeiGene Announces Interim Analysis Results of RATIONALE 303 Clinical Trial of Baizean for the Treatment of Second-line or Third-line Non-Small Cell Lung Cancer

BeiGene Announces Interim Analysis Results of RATIONALE 303 Clinical Trial of Baizean for the Treatment of Second-line or Third-line Non-Small Cell Lung Cancer

 Last Update: 2021-07-10
 Source: Internet
 Author: User

Tags

advanced

angiotensin 1 7

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

In the ITT population, the median OS of the Bazin® test arm was 17.
- In the Bazaan® test arm, 509 patients (95.
  3%) experienced at least one adverse event (TEAE) during treatment, the most common being anemia (28.
  5%) and elevated alanine aminotransferase (ALT; 19.
  9%) ) And cough (19.
  5%)
  .
  In contrast, in the docetaxel test arm, 254 patients (98.
  4%) experienced at least one TEAE, the most common being alopecia (47.
  3%), anemia (43.
  4%), and neutropenia (36.
  8%) )
- 206 patients (38.
  6%) and 193 patients (74.
  8%) of the Bazaan® test arm and the docetaxel test arm experienced grade 3 and above TEAEs, respectively
- 174 patients (32.
  6%) and 83 patients (32.
  2%) experienced severe TEAE in the test arm of Baizen® and the test arm of docetaxel, respectively
- There were 56 patients (10.
  5%) and 32 patients (12.
  4%) in the Baznan® test arm and the docetaxel test arm, respectively, who discontinued the trial treatment due to TEAE
- There were 32 patients (6%) and 11 patients (4.
  3%) died of TEAE in the test arm of Baizen® and the test arm of docetaxel, respectively.
- In the Baizean® test arm, hypothyroidism (7.
  5%) and pneumonia (2.
  2%) were the most common immune-mediated TEAEs of any grade and grade 3 and above, respectively

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.